{"schema_version":"secwatch.filing_event.v1","accession":"0001787400-26-000005","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.179730+00:00","generated_at":"2026-05-15T09:02:53.463127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029","bullets":["Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.","Full-year net loss $104.1M ($1.41 per share); Q4 net loss $27.4M ($0.37 per share).","NKX019 dose escalation advanced to 4 billion cells per dose in Ntrust-1 and Ntrust-2 trials.","Initial clinical data from Ntrust-1 and Ntrust-2 planned for presentation at a medical conference in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001787400-26-000005","json":"https://secwatch.observer/filing/0001787400-26-000005.json","markdown":"https://secwatch.observer/filing/0001787400-26-000005.md","text":"https://secwatch.observer/filing/0001787400-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/0001787400-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/nktx-20260325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:02:53.463127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8be35e55366a6a19205bfea7af7ab0b72d357cfb","claim":"Nkarta, Inc. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o, EPS $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter).","evidence_excerpt":"On March 25, 2026, Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/0001787400-26-000005-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o"},{"label":"EPS","value":"$1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}